Growth Metrics

AbCellera Biologics (ABCL) Depreciation and Depletion (2020 - 2026)

AbCellera Biologics filings provide 7 years of Depreciation and Depletion readings, the most recent being $5.9 million for Q1 2026.

  • Quarterly Depreciation and Depletion rose 34.23% to $5.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $19.8 million through Mar 2026, up 44.95% year-over-year, with the annual reading at $18.4 million for FY2025, 47.2% up from the prior year.
  • Depreciation and Depletion hit $5.9 million in Q1 2026 for AbCellera Biologics, up from $5.1 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $5.9 million in Q1 2026 and bottomed at $1.4 million in Q1 2022.
  • Average Depreciation and Depletion over 5 years is $3.4 million, with a median of $3.2 million recorded in 2024.
  • The largest annual shift saw Depreciation and Depletion plummeted 46.53% in 2024 before it skyrocketed 147.21% in 2025.
  • AbCellera Biologics' Depreciation and Depletion stood at $2.7 million in 2022, then surged by 40.75% to $3.9 million in 2023, then plummeted by 46.53% to $2.1 million in 2024, then skyrocketed by 147.21% to $5.1 million in 2025, then rose by 16.04% to $5.9 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Depreciation and Depletion are $5.9 million (Q1 2026), $5.1 million (Q4 2025), and $4.3 million (Q3 2025).